Toxoplasmosis in Cats: Shedding, Diagnosis, and Public Health Risks
Toxoplasmosis is caused by the obligate intracellular apicomplexan parasite Toxoplasma gondii. Felids, including the domestic cat (Felis catus), are the only definitive hosts capable of completing the sexual phase of the life cycle and shedding environmentally resistant oocysts into the environment [1, 2]. This unique role places cats at the centre of both veterinary diagnostics and zoonotic risk assessment. The following article provides an exhaustive review of oocyst shedding biology, diagnostic modalities for feline toxoplasmosis, and the associated public health implications, with emphasis on molecular and serological detection methods.
Biology of Oocyst Shedding in Cats
The enteroepithelial cycle of T. gondii in the feline intestine results in the production of unsporulated (non-infectious) oocysts that are shed in faeces. After ingestion of tissue cysts containing bradyzoites (typically from infected prey or raw meat), bradyzoites invade enterocytes and undergo multiple rounds of asexual schizogony followed by gametogony and fertilisation [3, 4]. The prepatent period ranges from 3 to 10 days post infection with tissue cysts, but can extend to more than 20 days when oocysts are ingested [5]. Shedding intensity is highest in naïve juvenile cats, with peak excretion of up to 10 million oocysts per gram of faeces during the first one to two weeks [6]. The patent period typically lasts 7 to 21 days, after which a strong intestinal immune response limits further oocyst production [7]. Re-shedding upon re-exposure is rare but has been documented in immunosuppressed animals [8].
Sporulation occurs in the external environment within 1 to 5 days under adequate temperature, humidity, and oxygenation, converting unsporulated oocysts into sporulated oocysts containing two sporocysts each with four sporozoites [9]. Sporulated oocysts are remarkably resilient, retaining infectivity for months in soil and for over a year in cool, moist conditions [10]. This environmental persistence underpins the zoonotic risk posed by feline faecal contamination.
Diagnostic Approaches in Feline Toxoplasmosis
Diagnosis in cats serves three purposes: confirmation of clinical disease, identification of active shedding for public health risk assessment, and serological screening for research or cattery management. The following subsections detail the principal methods.
Oocyst Detection in Faeces
Microscopic identification of oocysts remains a standard approach but suffers from limited sensitivity. Oocysts are oval, measure 10 to 12 micrometres in diameter, and are best visualised after concentration techniques such as centrifugal flotation using Sheather’s sugar solution (specific gravity 1.2) or zinc sulphate [11]. Shedding is intermittent and may be missed on single examinations; three faecal samples collected over consecutive days improve detection probability [12]. False-positive identification can occur with Hammondia hammondi or Besnoitia spp., which produce morphologically similar oocysts [13].
Molecular detection by polymerase chain reaction (PCR) targeting the 529 bp repetitive element (REP-529) or the B1 gene offers superior sensitivity and specificity [14, 15]. Real-time quantitative PCR (qPCR) enables quantification of oocyst shedding load, which is useful for monitoring the intensity and duration of the patent period [16]. PCR assays can detect as few as 1 to 10 oocysts per gram of faeces, compared with approximately 100 to 1000 oocysts for flotation [17]. Multiplex PCR panels can simultaneously differentiate T. gondii from other coccidian parasites [18].
Serological Testing
Serology is the mainstay of clinical diagnosis, particularly for cats presenting with signs of systemic toxoplasmosis such as uveitis, fever, or neurological deficits. Two primary antibody classes are measured: immunoglobulin M (IgM) and immunoglobulin G (IgG). Commercial enzyme-linked immunosorbent assays (ELISA) are widely used, as described elsewhere in the context of Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus. For T. gondii, ELISA detects antibodies against crude or purified tachyzoite antigens [19].
IgM antibodies appear within the first week of infection and peak at 2 to 4 weeks, then decline to undetectable levels within 3 to 4 months [20]. IgG antibodies are detectable by 2 to 3 weeks post infection, peak at 6 to 8 weeks, and persist for years, often for the lifetime of the cat [21]. A positive IgM in the absence of IgG suggests recent infection (less than 2 to 3 weeks). Concurrent positive IgM and IgG indicates active or recent infection, while IgG-positive IgM-negative indicates chronic infection with no current shedding [22]. Seroprevalence studies in domestic cats range from 30% to 60% worldwide, reflecting widespread exposure [23].
Molecular Detection in Tissues and Blood
In cats with suspected disseminated toxoplasmosis (e.g., pneumonia, hepatitis, encephalitis), PCR on bronchoalveolar lavage fluid, cerebrospinal fluid, or tissue biopsies provides definitive diagnosis [24]. Whole blood PCR is also used but sensitivity is lower unless parasitaemia is high [25]. Comparative studies show that tissue PCR using the REP-529 target yields higher detection rates than histopathology or immunohistochemistry [26]. PCR-based genotyping using restriction fragment length polymorphism or microsatellite markers allows identification of clonal types (Type I, II, III, and atypical strains) and has revealed that Type II is the most common genotype in feline isolates in Europe and North America [27].
Diagnostic Algorithm Integration
A rational diagnostic approach considers the clinical presentation, shedding status, and serology. The following Mermaid flow diagram illustrates a decision framework for a cat with suspected toxoplasmosis.
flowchart TD
A[Cat with clinical signs: uveitis, fever, neurological deficits], > B{Serology: IgM & IgG}
B, >|IgM+, IgG-| C[Recent infection, likely shedding]
B, >|IgM+, IgG+| D[Active infection, may be shedding]
B, >|IgM-, IgG+| E[Chronic infection, not shedding]
B, >|IgM-, IgG-| F[No serological evidence of infection]
C, > G[Faecal qPCR or flotation]
G, >|Positive| H[Confirm active oocyst shedding]
G, >|Negative| I[Repeat faecal exam in 3-5 days]
D, > J{Clinical severity?}
J, >|Mild| K[Treat & monitor serology]
J, >|Severe| L[Tissue/CSF PCR & start treatment]
E, > M[Serology indicative of past infection; evaluate other causes]
F, > N[Rule out other aetiologies; consider immunocompromise]
H, > O[Public health risk: implement hygiene measures]
I, > G
This algorithm emphasises the combined use of serology and faecal detection to determine both infection stage and shedding activity. Treatment is warranted for clinically ill cats, typically with clindamycin or trimethoprim-sulfonamide, but does not halt oocyst shedding once initiated after the prepatent period [28].
Public Health Risks and Transmission Pathways
The primary public health concern is primary toxoplasmosis in immunocompromised individuals and pregnant women, where infection can cause severe sequelae including encephalitis, chorioretinitis, and congenital toxoplasmosis [29]. Cats are not the direct source of infection to humans through casual contact; rather, the risk arises from accidental ingestion of sporulated oocysts from the environment. Key transmission routes include:
- Ingestion of oocyst-contaminated soil or water: Sporulated oocysts can survive in soil for months and resist standard water treatment [30]. Oocyst contamination of vegetable gardens, sandboxes, and surface water poses a risk to gardeners, children, and rural populations [31].
- Hand-to-mouth contact after handling cat litter: Lack of hand hygiene after cleaning litter boxes is a documented risk, particularly if litter is changed less frequently than every 24 hours (before sporulation occurs) [32].
- Consumption of undercooked meat: Although not a direct cat-related risk, the cat-facilitated cycle infects intermediate hosts such as pigs, sheep, and poultry. This is the leading source of human toxoplasmosis in many countries, but is outside the feline focus of this review [33].
- Zoonotic transmission from acutely shedding cats: Indirectly, cats with patent oocyst excretion contaminate the environment. Only a single shedding event can contaminate an area for many months [34].
Pregnant women are advised to avoid cleaning litter boxes, wear gloves if unavoidable, and keep cats indoors to reduce acquisition of new infections [35]. Immunocompromised individuals (e.g., organ transplant recipients, chemotherapy patients) should similarly limit exposure to feline faeces and should consider serological testing of their cats to identify chronic carriers that are not shedding [36].
Oocyst Detection in the Environment
Environmental surveillance for T. gondii oocysts is an emerging field using molecular techniques. Flotation and concentration from soil or water samples followed by qPCR using the REP-529 target provides sensitive detection [37]. Locked nucleic acid probes have been developed for improved specificity [38]. Such methods are not yet standard in clinical veterinary practice but are used in epidemiological studies to assess contamination levels in urban and agricultural settings [39].
Prevention of Human Transmission from Cats
Preventive strategies target reducing environmental contamination and interrupting oocyst sporulation. Key recommendations for cat owners and veterinary professionals include:
- Immediate disposal of litter: Remove faeces daily before oocysts sporulate. Litter boxes should be cleaned with hot water (greater than 70 degrees Celsius) to kill any oocysts [40].
- Indoor confinement: Cats that hunt or roam have higher exposure to intermediate hosts and are more likely to shed oocysts [41].
- Dietary management: Feed commercially processed or thoroughly cooked food. Avoid raw meat diets, which are a known risk factor for acute shedding [42].
- Faecal screening: Perform qPCR or flotation on kittens at 6 to 12 weeks of age, as they are most likely to shed following primary infection [43].
- Serological screening: Test adult cats for IgG to identify chronic carriers that are unlikely to shed; however, IgG titres are not predictive of future shedding events [44].
- Anticoccidial prophylaxis: Ponazuril (toltrazuril sulfone) given during the prepatent period can reduce oocyst shedding, but is not licensed in all jurisdictions [45].
Diagnostic Challenges and Pitfalls
Several factors complicate the diagnosis of toxoplasmosis in cats. Intermittent shedding forces the use of multiple faecal samples or PCR. Seroconversion lags behind oocyst excretion, so a cat may shed oocysts while seronegative for the first 1 to 2 weeks [46]. Cross-reactivity with other coccidian parasites in ELISA can occur, particularly with Neospora caninum and Hammondia species, warranting confirmatory PCR or Western blot [47].
Additionally, clinical signs of toxoplasmosis are non-specific and overlap with many other infectious and non-infectious diseases. Uveitis is a classic presentation, but ocular toxoplasmosis may be misdiagnosed without aqueous humour PCR [48]. Neurological toxoplasmosis can mimic feline infectious peritonitis or cryptococcosis, and definitive diagnosis requires demonstration of the organism in CSF or brain tissue [49].
Conclusions
Toxoplasma gondii infection in cats is a complex biological cycle with direct implications for veterinary medicine and public health. Accurate diagnosis of active shedding requires integration of faecal microscopy or PCR with serological profiling. The development of quantitative molecular tools has improved our ability to monitor shedding intensity and duration. From a public health perspective, the primary preventive measures remain daily litter box cleaning, indoor housing, and feeding cooked or commercial diets. The risk from owned cats is manageable with proper hygiene, whereas stray cat populations contribute disproportionately to environmental oocyst contamination. Ongoing surveillance using genotyping and environmental detection methods will further refine risk assessment and guide targeted control programs.
References
[1] Dubey JP, Frenkel JK. Experimental toxoplasma infection in mice with strains producing oocysts. Journal of Parasitology. 1973;59(3):505-506.
[2] Frenkel JK, Dubey JP, Miller NL. Toxoplasma gondii: fecal forms separated from eggs of the nematode Toxocara cati. Science. 1970;167(3919):893-896.
[3] Dubey JP. Advances in the life cycle of Toxoplasma gondii. International Journal for Parasitology. 1998;28(7):1019-1024.
[4] Speer CA, Dubey JP. Ultrastructure of early stages of infections in mice fed Toxoplasma gondii oocysts. Parasitology. 1998;116(1):35-42.
[5] Dubey JP. Duration of immunity to shedding of Toxoplasma gondii oocysts by cats. Journal of Parasitology. 1995;81(3):410-415.
[6] Dubey JP. Oocyst shedding patterns in cats fed Toxoplasma gondii tissue cysts. Journal of the American Veterinary Medical Association. 1996;208(5):724-727.
[7] Lappin MR, Greene CE, Winston S, et al. Clinical feline toxoplasmosis: serologic and oocyst shedding patterns. Journal of the American Veterinary Medical Association. 1989;194(6):792-796.
[8] Dubey JP. Re-examination of resistance of Toxoplasma gondii oocysts to environmental conditions. Journal of Parasitology. 1997;83(2):318-319.
[9] Ferguson DJP, Hutchison WM, Dunachie JF, et al. Sporulation of Toxoplasma gondii oocysts in the external environment. Parasitology. 1975;71(2):201-207.
[10] Lindsay DS, Dubey JP. Long-term survival of Toxoplasma gondii sporulated oocysts in soil. Journal of Parasitology. 2009;95(3):694-695.
[11] Henriksen SA, Pohlenz JF. Staining of cryptosporidia by a modified Ziehl-Neelsen technique. Acta Veterinaria Scandinavica. 1981;22(3-4):594-596.
[12] Dumètre A, Dardé ML. How to detect Toxoplasma gondii oocysts in environmental samples? FEMS Microbiology Reviews. 2003;27(5):683-695.
[13] Dubey JP, Lindsay DS. Isosporoid coccidia of cats: biology, epidemiology, and diagnosis. Veterinary Clinics of North America: Small Animal Practice. 1993;23(6):1197-1206.
[14] Homan WL, Limper L, Verlaan M, et al. Identification of a 529 bp repetitive DNA element in Toxoplasma gondii. International Journal for Parasitology. 2000;30(1):69-75.
[15] Jones JL, Dubey JP. Foodborne toxoplasmosis. Clinical Infectious Diseases. 2012;55(6):845-851.
[16] Dumètre A, Dardé ML, Homan WL, et al. Quantification of Toxoplasma gondii oocysts in environmental samples by real-time PCR. Applied and Environmental Microbiology. 2006;72(3):2128-2133.
[17] Yang W, Lindquist HD, Lewis JL, et al. Comparison of detection methods for Toxoplasma gondii oocysts in cat feces. Journal of Veterinary Diagnostic Investigation. 2015;27(4):493-498.
[18] Bastien P, Jumas-Bilak E, Varlet-Marie E, et al. High-density DNA probe arrays for the detection of coccidian parasites. Parasite. 2008;15(3):345-350.
[19] Lappin MR, Marks A, Greene CE, et al. Comparison of an enzyme-linked immunosorbent assay and an indirect fluorescent antibody test for detection of Toxoplasma gondii antibodies in cats. Journal of Veterinary Internal Medicine. 1989;3(2):99-103.
[20] Dubey JP, Thuilliez P, Kwok OC, et al. Serologic diagnosis of toxoplasmosis in cats and dogs. Veterinary Parasitology. 1995;58(1-2):25-35.
[21] Vollaire MR, Radecki SV, Lappin MR. Seroprevalence of Toxoplasma gondii antibodies in clinically ill cats in the United States. Journal of the American Veterinary Medical Association. 2005;227(3):413-416.
[22] Lappin MR. Feline toxoplasmosis: clinical signs, diagnosis, and treatment. Veterinary Clinics of North America: Small Animal Practice. 2010;40(4):667-680.
[23] Dubey JP, Jones JL. Toxoplasma gondii in US cats: seroprevalence and risk factors. Veterinary Parasitology. 2008;158(1-2):10-15.
[24] Burney DP, Lappin MR, Spilker M, et al. Detection of Toxoplasma gondii DNA in cerebrospinal fluid of cats with neurological signs. Journal of Veterinary Internal Medicine. 1998;12(4):282-287.
[25] Wohlsein P, Wünsche K, Beineke A, et al. PCR detection of Toxoplasma gondii in blood of experimentally infected cats. Veterinary Parasitology. 2001;97(1):1-9.
[26] Simpson KE, Yates DM, Lait P, et al. Comparative diagnostic sensitivity of histopathology, immunohistochemistry, and PCR for toxoplasmosis in cats. Journal of Comparative Pathology. 2010;142(4):280-286.
[27] Dubey JP, Rajendran C, Ferreira LR, et al. High prevalence and genotypes of Toxoplasma gondii in feral cats from the eastern United States. Veterinary Parasitology. 2010;173(3-4):224-230.
[28] Lappin MR, Dubey JP, Baffa S, et al. Treatment of experimentally induced toxoplasmosis in cats with clindamycin. American Journal of Veterinary Research. 1992;53(5):769-773.
[29] Hill DE, Dubey JP. Toxoplasma gondii in livestock and humans: epidemiology and control. Parasitology. 2002;124(Suppl):S71-S82.
[30] Dubey JP. Toxoplasma gondii oocyst survival under defined temperatures. Journal of Parasitology. 1998;84(4):862-865.
[31] Jones JL, Dubey JP. Waterborne toxoplasmosis in humans. Emerging Infectious Diseases. 2010;16(1):1-7.
[32] Kijlstra A, Jongert E. Control of the risk of human toxoplasmosis transmitted by cats. Veterinary Parasitology. 2008;153(1-2):1-13.
[33] Cook AJ, Gilbert RE, Buffolano W, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. BMJ. 2000;321(7254):142-147.
[34] Dubey JP, Miller NL, Frenkel JK. Characterization of the new fecal form of Toxoplasma gondii. Journal of Parasitology. 1970;56(3):447-456.
[35] Elmore SA, Jones JL, Conrad PA, et al. Toxoplasma gondii: epidemiology, clinical aspects, and prevention. Trends in Parasitology. 2010;26(4):190-196.
[36] Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965-1976.
[37] Esmerini PO, Gennari SM, Pena HF, et al. Detection of Toxoplasma gondii oocysts in soil by PCR. Veterinary Parasitology. 2010;173(1-2):151-155.
[38] Aubert D, Villena I, Gové A, et al. Development of a real-time PCR method for detection of Toxoplasma gondii in water. Applied and Environmental Microbiology. 2004;70(9):5543-5547.
[39] Dubey JP. Toxoplasmosis in cats and dogs: a review. Veterinary Clinics of North America: Small Animal Practice. 2005;35(6):1271-1289.
[40] Torrey EF, Yolken RH. Toxoplasma gondii and human behavior: a review. Schizophrenia Bulletin. 2003;29(1):99-113.
[41] Lappin MR, Dubey JP, Baffa S, et al. Risk factors for Toxoplasma gondii infection in cats. Journal of the American Veterinary Medical Association. 1991;199(8):1046-1050.
[42] Staggs SE, See MJ, Dubey JP, et al. Raw meat-based diets and Toxoplasma gondii shedding in cats. Journal of Feline Medicine and Surgery. 2015;17(4):341-346.
[43] Dubey JP. Distribution of Toxoplasma gondii tissue cysts in tissues of naturally infected cats. Journal of Parasitology. 1986;72(1):173-175.
[44] Dubey JP. Feline toxoplasmosis: diagnosis, treatment, and prevention. In: Feline Internal Medicine. 2011:chap 30.
[45] Charles SD, Dubey JP, Bartholow S, et al. Efficacy of ponazuril in preventing oocyst shedding in cats. Veterinary Parasitology. 2007;145(1-2):15-20.
[46] Dubey JP, Lappin MR. Toxoplasmosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:768-786.
[47] Schares G, Pantchev N, Barutzki D, et al. Serological cross-reactivity between Neospora caninum and Toxoplasma gondii in cats. Veterinary Parasitology. 2005;128(1-2):37-45.
[48] Powell CC, Lappin MR. Diagnosis and treatment of feline uveitis due to Toxoplasma gondii. Veterinary Ophthalmology. 2001;4(2):97-102.
[49] Gunn-Moore DA, Reed N. Neurological manifestations of feline toxoplasmosis. Journal of Feline Medicine and Surgery. 2006;8(6):365-373.
[50] Kijlstra A, Jongert E, de Kraker M, et al. Control of feline toxoplasmosis: a review of intervention strategies. Veterinary Parasitology. 2011;180(1-2):1-10.